Brodalumab as an Alternative to Ustekinumab in Psoriasis Brodalumab as an Alternative to Ustekinumab in Psoriasis
Is brodalumab effective in treating moderate-to-severe psoriasis in patients who do not achieve adequate response with ustekinumab?The British Journal of Dermatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 18, 2019 Category: Consumer Health News Tags: Dermatology Journal Article Source Type: news

Medical News Today: Stelara vs. Humira: What's the difference?
Stelara and Humira are two biologics that help treat immune conditions, such as psoriatic arthritis and Crohn ’s disease. In this article, we look at the similarities and differences in their effects, benefits, and risks. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - March 14, 2019 Category: Consumer Health News Tags: Rheumatology Source Type: news

New Phase 3 Stelara ® (Ustekinumab) Data Show Positive Results as Maintenance Therapy in Adults with Moderate to Severe Ulcerative Colitis
(Source: Johnson and Johnson)
Source: Johnson and Johnson - March 11, 2019 Category: Pharmaceuticals Source Type: news

J & J Raises U.S. Prices on Around Two Dozen Drugs J & J Raises U.S. Prices on Around Two Dozen Drugs
Johnson& Johnson raised U.S. prices on around two dozen prescription drugs on Thursday, including the psoriasis treatment Stelara (ustekinumab), prostate cancer drug Zytiga (abiraterone) and blood thinner Xarelto (rivaroxaban), all among its top-selling products.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 14, 2019 Category: Consumer Health News Tags: Medscape Today News Source Type: news

J & J raises U.S. drug prices
Johnson& Johnson raised U.S. prices on around two dozen drugs, including psoriasis treatment, Stelara, prostate cancer drug, Zytiga, and blood thinner, Xarelto. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - January 11, 2019 Category: Pharmaceuticals Source Type: news

J & amp;J raises U.S. drug prices
Johnson& Johnson raised U.S. prices on around two dozen drugs, including psoriasis treatment, Stelara, prostate cancer drug, Zytiga, and blood thinner, Xarelto. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - January 11, 2019 Category: Pharmaceuticals Source Type: news

J & J raises U.S. prices on around two dozen drugs
Johnson& Johnson raised U.S. prices on around two dozen prescription drugs on Thursday, including the psoriasis treatment Stelara, prostate cancer drug Zytiga and blood thinner Xarelto, all among its top-selling products. (Source: Reuters: Health)
Source: Reuters: Health - January 11, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

Noninfectious Pneumonia Tied to Ustekinumab Use Noninfectious Pneumonia Tied to Ustekinumab Use
Treatment with ustekinumab (Stelara, Janssen Biotech) may be associated with noninfectious pneumonia, according to a report by the U.S. Food and Drug Administration (FDA).Reuters Health Information (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - December 28, 2018 Category: Intensive Care Tags: Pulmonary Medicine News Source Type: news

Two-Drug Regimen Fails to Stem Psoriasis Relapse
(MedPage Today) -- Study looks at costimulatory blockade with abatacept after stopping ustekinumab (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - December 18, 2018 Category: Primary Care Source Type: news

Minimal Disease Activity and Acceptable Symptom State in PsA Minimal Disease Activity and Acceptable Symptom State in PsA
A new study provides evidence of the safety and efficacy of ustekinumab in psoriatic arthritis in a real-world setting.Journal of Clinical Rheumatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 26, 2018 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news

ACR: IL-12/23 Blocker Offers Long-Term Benefits in SLE
(MedPage Today) -- Responses were sustained out to 1 year with ustekinumab (Source: MedPage Today Rheumatology)
Source: MedPage Today Rheumatology - October 24, 2018 Category: Rheumatology Source Type: news

New Phase 2 Data Show Stelara ® (Ustekinumab) Sustained Improvement in Disease Activity in Adults With Systemic Lupus Erythematosus Through One Year
(Source: Johnson and Johnson)
Source: Johnson and Johnson - October 23, 2018 Category: Pharmaceuticals Source Type: news

Stelara a Hit in Ulcerative Colitis
(MedPage Today) -- Clinical remission achieved with two different doses of interleukin 12/23 blocker (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - October 11, 2018 Category: Gastroenterology Source Type: news

J & J's Stelara Succeeds in Ulcerative Colitis Study J & J's Stelara Succeeds in Ulcerative Colitis Study
Johnson& Johnson said on Tuesday its blockbuster drug Stelara (ustekinumab) was found to be effective in treating ulcerative colitis (UC) in a late-stage trial.Reuters Health Information (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 10, 2018 Category: Consumer Health News Tags: Gastroenterology News Source Type: news

New phase 3 data show single dose of stelara ® (ustekinumab) induces clinical remission and response in adults with moderate to severe ulcerative colitis
(Source: Johnson and Johnson)
Source: Johnson and Johnson - October 10, 2018 Category: Pharmaceuticals Source Type: news

J & amp;J blockbuster find late-stage trial success in chronic bowel disease study
Stelara was previously approved for psoriasis, psoriatic arthritis and Crohn's disease (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - October 10, 2018 Category: Pharmaceuticals Source Type: news

J & J's Stelara succeeds in chronic bowel disease study
Johnson& Johnson said on Tuesday its blockbuster drug Stelara was found to be effective in treating a chronic bowel disease in a late-stage trial. (Source: Reuters: Health)
Source: Reuters: Health - October 9, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

AbbVie Announces Patient-Reported Outcomes Data from Three Pivotal Phase 3 Studies of Risankizumab, Showing Significant Improvements in Health-Related Quality of Life for Patients with Psoriasis
Pooled analyses from ultIMMa-1 and ultIMMa-2 studies showed significantly more patients treated with risankizumab were symptom-free (psoriasis symptom scale [PSS] score of 0) compared to placebo and STELARA® (ustekinumab) after 16 weeks and at one year... Biopharmaceuticals, Dermatology AbbVie, Risankizumab, psoriasis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - September 13, 2018 Category: Pharmaceuticals Source Type: news

Ustekinumab for Crohn's Disease: Long-term Efficacy, Safety Ustekinumab for Crohn's Disease: Long-term Efficacy, Safety
This study assessed long-term extension data of ustekinumab for Crohn's disease, demonstrating the maintenance of response and remission and continued safety through 92 weeks.Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 14, 2018 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Enthesitis in PsA: A New Focus of Treatment?
(MedPage Today) -- Targeting IL-23 with ustekinumab cleared enthesitis in three-quarters of patients (Source: MedPage Today Dermatology)
Source: MedPage Today Dermatology - June 23, 2018 Category: Dermatology Source Type: news

Ustekinumab: Novel Help in Vasculitis?
(MedPage Today) -- Steroid-sparing effects demonstrated in small pilot study (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - May 24, 2018 Category: Primary Care Source Type: news

Predictors of Response to Vedolizumab and Ustekinumab in IBD Predictors of Response to Vedolizumab and Ustekinumab in IBD
What factors and patient characteristics might help predict initial and long-term response to vedolizumab and ustekinumab in inflammatory bowel disease?Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 8, 2018 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Long-term Efficacy, Safety of Ustekinumab in Refractory CD Long-term Efficacy, Safety of Ustekinumab in Refractory CD
This study evaluated the long-term efficacy and safety of ustekinumab in anti-TNF refractory Crohn's disease patients.Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 12, 2018 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Fecal Microbiota Profile Predicts Ustekinumab Response in Crohn's Fecal Microbiota Profile Predicts Ustekinumab Response in Crohn's
Data on patients ’ fecal microbiota can be used to predict their response to ustekinumab therapy for Crohn's disease, researchers report.Reuters Health Information (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - March 26, 2018 Category: Pathology Tags: Gastroenterology News Source Type: news

Experimental Biologic Surpasses Ustekinumab for Psoriasis Experimental Biologic Surpasses Ustekinumab for Psoriasis
A biologic under investigation for severe psoriasis has topped one of the most effective therapies on the market in head-to-head phase 3 trials.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - February 20, 2018 Category: Allergy & Immunology Tags: Dermatology News Source Type: news

Risankizumab Resolves Psoriasis in Half of Patients
(MedPage Today) -- Superior to ustekinumab for many endpoints in two RCTs (Source: MedPage Today Dermatology)
Source: MedPage Today Dermatology - February 19, 2018 Category: Dermatology Source Type: news

Ustekinumab Makes Inroads in Crohn's Disease
(MedPage Today) -- Docs opt for psoriasis drug when anti-TNF agents fail (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - January 22, 2018 Category: Gastroenterology Source Type: news

Novartis new data reinforces superiority of Cosentyx(R) versus Stelara(R) in achieving skin clearance for psoriasis patients
Results from CLARITY study show Cosentyx® (secukinumab) was significantly more effective than Stelara® (ustekinumab) in delivering clear and almost clear skin at 12 weeks and at 16 weeks(1) Data support findings from the CLEAR study, which found... Biopharmaceuticals Novartis, Cosentyx, secukinumab, plaque psoriasis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 16, 2018 Category: Pharmaceuticals Source Type: news

Biological Therapies and Improvements in QoL in Psoriasis Biological Therapies and Improvements in QoL in Psoriasis
This study compared the effectiveness of adalimumab, etanercept and ustekinumab on improvements in HRQoL in patients with psoriasis. What factors are associated with these improvements?The British Journal of Dermatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 16, 2018 Category: Consumer Health News Tags: Dermatology Journal Article Source Type: news

Stelara ® (ustekinumab) shows positive results in treatment of systemic lupus erythematosus in phase 2 trial
(Source: Johnson and Johnson)
Source: Johnson and Johnson - November 6, 2017 Category: Pharmaceuticals Source Type: news

J & J's Stelara shows promise against lupus in study
(Reuters) - Johnson& Johnson's blockbuster psoriasis drug Stelara led to a significant reduction in disease activity in patients with systemic lupus compared with a placebo in a midstage clinical trial, according to data released on Saturday. (Source: Reuters: Health)
Source: Reuters: Health - November 5, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Risankizumab outperforms ustekinumab in psoriasis trial
The IL-23 inhibitor risankizumab was superior to ustekinumab in a phase two trial of adult patients with moderate-to-severe chronic plaque psoriasis, researchers report. (Source: Dermatology Times)
Source: Dermatology Times - October 19, 2017 Category: Dermatology Source Type: news

FDA Clears Ustekinumab (Stelara) for Plaque Psoriasis in Teens FDA Clears Ustekinumab (Stelara) for Plaque Psoriasis in Teens
For at least two thirds of patients aged 12 to 17 years who were treated with ustekinumab, cleared skin or minimal psoriasis was achieved at week 12 in a phase 3 study.FDA Approvals (Source: Medscape Med Students Headlines)
Source: Medscape Med Students Headlines - October 16, 2017 Category: Universities & Medical Training Tags: Dermatology News Alert Source Type: news

Janssen announces u.s. fda approval of stelara ® (ustekinumab) for the treatment of adolescents with moderate to severe plaque psoriasis
(Source: Johnson and Johnson)
Source: Johnson and Johnson - October 14, 2017 Category: Pharmaceuticals Source Type: news

J & J psoriasis drug gets expanded U.S. approval for teens
(Reuters) - Johnson& Johnson said on Friday it has received an expanded U.S. approval for its blockbuster psoriasis drug Stelara to treat adolescent patients aged 12 and over with moderate to severe cases of the unsightly skin condition. (Source: Reuters: Health)
Source: Reuters: Health - October 13, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Janssen Announces FDA Approval of Stelara (ustekinumab) for the Treatment of Adolescents with Moderate to Severe Plaque Psoriasis
Horsham, Pa., October 13, 2017 ― Janssen Biotech, Inc., announced today that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for Stelara (ustekinumab) for the treatment of adolescents (12 years of age or older) with... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - October 13, 2017 Category: Drugs & Pharmacology Source Type: news

NICE approves new type of treatment for Crohn ’s disease
Following NICE recommendations, patients with Crohn ’s disease will have routine NHS access to drug ustekinumab, which offers a new way of treating the condition. (Source: NHS Networks)
Source: NHS Networks - June 22, 2017 Category: UK Health Source Type: news

UK NICE recommends Janssen ’s Ustekinumab treatment for Crohn’s disease
The UK ’s National Institute for Health and Care Excellence (NICE) has recommended Janssen’s Ustekinumab for the treatment of patients with moderate-to-severe Crohn’s disease. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - June 19, 2017 Category: Pharmaceuticals Source Type: news

Risankizumab More Effective in Psoriasis Than Ustekinumab in Early Trial Risankizumab More Effective in Psoriasis Than Ustekinumab in Early Trial
Selective inhibition of IL-23 with risankizumab may be more effective in treating psoriasis than the less specific ustekinumab; more studies are needed to confirm results and assess.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - April 20, 2017 Category: Allergy & Immunology Tags: Dermatology News Source Type: news

One Biologic Bests Another in Head-to-Head Psoriasis Trial
(MedPage Today) -- Taltz turns in better results than Stelara on severity indices (Source: MedPage Today Dermatology)
Source: MedPage Today Dermatology - March 6, 2017 Category: Dermatology Source Type: news

New Results From Second Phase 3 Study Show Significant Efficacy of Guselkumab and Superiority Versus Humira ® in Treatment of Moderate to Severe Plaque Psoriasis
Additional Phase 3 Study Data Show Significant Efficacy of Guselkumab in Patients Experiencing Inadequate Response to STELARA ® in the Treatment of Moderate to Severe Plaque Psoriasis (Source: Johnson and Johnson)
Source: Johnson and Johnson - March 3, 2017 Category: Pharmaceuticals Source Type: news

Janssen Submits Application Seeking FDA Approval Of Stelara ® (Ustekinumab) For The Treatment Of Adolescents With Moderate To Severe Plaque Psoriasis
(Source: Johnson and Johnson)
Source: Johnson and Johnson - December 17, 2016 Category: Pharmaceuticals Source Type: news

Janssen Submits Application Seeking FDA Approval of STELARA(R) (Ustekinumab) for the Treatment of Adolescents with Moderate to Severe Plaque Psoriasis
HORSHAM, Pa., Dec. 16, 2016 -- (Healthcare Sales & Marketing Network) -- Janssen Biotech, Inc. (Janssen) announced today the submission of a Supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking approval ... Biopharmaceuticals, Dermatology, FDA Janssen, STELARA, ustekinumab, Psoriasis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 16, 2016 Category: Pharmaceuticals Source Type: news

Health Canada approves STELARA(R) for the treatment of adults with moderately to severely active Crohn's disease
STELARA® offers a new approach to treating Crohn's disease in Canada, which has one of the highest rates of this inflammatory bowel disease worldwide1 TORONTO, Dec. 14, 2016 (Healthcare Sales & Marketing Network) - Janssen Inc. announced today that... Biopharmaceuticals, Gastroenterology, Regulatory Janssen Pharmaceutical, STELARA, ustekinumab, Crohn's disease (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 14, 2016 Category: Pharmaceuticals Source Type: news

Stelara (Ustekinumab) for the Treatment of Moderate to Severe Crohn ’s Disease
Developed by Janssen Biotech, Stelara (Ustekinumab) is indicated for the treatment of moderate to severely active Crohn's disease. (Source: Drug Development Technology)
Source: Drug Development Technology - November 29, 2016 Category: Pharmaceuticals Source Type: news

Drug Stelara May Ease Crohn's Disease
Title: Drug Stelara May Ease Crohn's DiseaseCategory: Health NewsCreated: 11/17/2016 12:00:00 AMLast Editorial Review: 11/18/2016 12:00:00 AM (Source: MedicineNet Digestion General)
Source: MedicineNet Digestion General - November 18, 2016 Category: Nutrition Source Type: news

Drug Stelara May Ease Crohn's Disease
Medication is potentially helpful for those who didn't find relief from other treatments, researchers say (Source: WebMD Health)
Source: WebMD Health - November 17, 2016 Category: Consumer Health News Source Type: news

Drug Stelara May Ease Crohn's Disease
Medication is potentially helpful for those who didn't find relief from other treatments, researchers say Source: HealthDay Related MedlinePlus Pages: Crohn's Disease, Medicines (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - November 17, 2016 Category: Consumer Health News Source Type: news

Drug Stelara May Ease Crohn's Disease
THURSDAY, Nov. 17, 2016 -- People with moderate to severe Crohn's disease who haven't responded to other treatments may benefit from the drug ustekinumab (Stelara), a new study suggests. Stelara is a monoclonal antibody that blocks the action of... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - November 17, 2016 Category: Journals (General) Source Type: news

Arthritis drug significantly effective in treating Crohn's disease, study finds
Ustekinumab, a human antibody used to treat arthritis, significantly induces response and remission in patients with moderate to severe Crohn ’s disease, researchers have shown that. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - November 17, 2016 Category: Science Source Type: news